Medtronic-Sponsored Economic Analysis Supports CRT Devices As Cost-Effective
Executive Summary
New analysis from the Medtronic-sponsored REVERSE trial shows that patients with mild heart failure receiving CRT therapy had an ICER (incremental cost effectiveness ratio) of $8,840 per QALY, compared to those not receiving CRT.